Insider Trading Alert - MDVN, BWLD And LMAT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 6, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.44 to $8,899,995.42.

Highlighted Stocks Traded by Insiders:

Medivation (MDVN) - FREE Research Report

Bierly Rick, who is Chief Financial Officer at Medivation, sold 3,785 shares at $124.83 on May 6, 2015. Following this transaction, the Chief Financial Officer owned 16,226 shares meaning that the stake was reduced by 18.91% with the 3,785-share transaction.

The shares most recently traded at $121.68, down $3.15, or 2.59% since the insider transaction. Historical insider transactions for Medivation go as follows:

  • 4-Week # shares sold: 1,390
  • 12-Week # shares sold: 125,829
  • 24-Week # shares sold: 237,539

The average volume for Medivation has been 940,000 shares per day over the past 30 days. Medivation has a market cap of $9.5 billion and is part of the health care sector and drugs industry. Shares are up 21.32% year-to-date as of the close of trading on Wednesday.

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company has a P/E ratio of 35.3. Currently, there are 11 analysts who rate Medivation a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDVN - FREE

TheStreet Quant Ratings rates Medivation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Medivation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Buffalo Wild Wings (BWLD) - FREE Research Report

Schmidt James M, who is Chief Operating Officer at Buffalo Wild Wings, sold 1,000 shares at $157.75 on May 6, 2015. Following this transaction, the Chief Operating Officer owned 36,996 shares meaning that the stake was reduced by 2.63% with the 1,000-share transaction.

Twinem Mary J, who is Exec VP, CFO & Treasurer at Buffalo Wild Wings, sold 500 shares at $157.75 on May 6, 2015. Following this transaction, the Exec VP, CFO & Treasurer owned 36,998 shares meaning that the stake was reduced by 1.33% with the 500-share transaction.

The shares most recently traded at $155.53, down $2.22, or 1.43% since the insider transaction. Historical insider transactions for Buffalo Wild Wings go as follows:

  • 4-Week # shares bought: 315
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 315
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 315
  • 24-Week # shares sold: 14,000

The average volume for Buffalo Wild Wings has been 459,100 shares per day over the past 30 days. Buffalo Wild Wings has a market cap of $3.0 billion and is part of the services sector and leisure industry. Shares are down 12.97% year-to-date as of the close of trading on Wednesday.

Buffalo Wild Wings, Inc. owns, operates, and franchises restaurants. The company's restaurants provide various food products, and nonalcoholic and alcoholic beverages. The company has a P/E ratio of 31.5. Currently, there are 12 analysts who rate Buffalo Wild Wings a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BWLD - FREE

TheStreet Quant Ratings rates Buffalo Wild Wings as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, growth in earnings per share, increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Buffalo Wild Wings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LeMaitre Vascular (LMAT) - FREE Research Report

Roberts David B, who is President and Director at LeMaitre Vascular, sold 11,000 shares at $9.27 on May 6, 2015. Following this transaction, the President and Director owned 264,839 shares meaning that the stake was reduced by 3.99% with the 11,000-share transaction.

The shares most recently traded at $9.77, up $0.50, or 5.12% since the insider transaction. Historical insider transactions for LeMaitre Vascular go as follows:

  • 4-Week # shares sold: 6,065
  • 12-Week # shares sold: 18,065
  • 24-Week # shares sold: 114,930

The average volume for LeMaitre Vascular has been 36,300 shares per day over the past 30 days. LeMaitre Vascular has a market cap of $168.6 million and is part of the health care sector and health services industry. Shares are up 25.88% year-to-date as of the close of trading on Wednesday.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease worldwide. The stock currently has a dividend yield of 1.66%. The company has a P/E ratio of 41.9. Currently, there are 5 analysts who rate LeMaitre Vascular a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LMAT - FREE

TheStreet Quant Ratings rates LeMaitre Vascular as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full LeMaitre Vascular Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI